* Cortex Pharmaceuticals Inc., of Irvine, Calif., paidAlkermes Inc., of Cambridge, Mass., a three-year $1million promissory note to reacquire rights to calpaininhibitors for neurodegenerative disorders. Alkermes willget further payments if Cortex partners or sells calpaininhibitor products. As a result of the deal, litigation wasdropped that revolved around whether cerebralvasospasm is a neurodegenerative disease or vasculardisorder. (See BioWorld Today, Nov. 23, 1993, p. 2.)
* Rhone-Poulenc Rorer Inc., of Collegeville, Pa., saidTaxotere (docetaxel) was approved in Brazil for treatmentof breast and non-small cell lung cancer.
(c) 1997 American Health Consultants. All rights reserved.